CN109651509B

CN109651509B - Humanized monoclonal antibody for resisting CD20 and preparation thereof

Info

Publication number: CN109651509B
Application number: CN201811640539.8A
Authority: CN
Inventors: 杨林; 游凤涛
Original assignee: Perongen Biotherapeutics Suzhou Co ltd
Current assignee: Perongen Biotherapeutics Suzhou Co ltd
Priority date: 2018-12-29
Filing date: 2018-12-29
Publication date: 2021-01-22
Anticipated expiration: 2038-12-29
Also published as: CN109651509A

Abstract

The invention provides a humanized monoclonal antibody resisting CD20 and a preparation thereof. In particular, the invention provides a novel anti-CD 20 humanized antibody. The antibody of the invention can be combined with CD20 antigen with high specificity, and has higher affinity and bioactivity, low immunogenicity, stable structure and good pharmacy. The humanized antibody has good stability in the antibody preparation, and is used for preparing a medicament for preventing or treating CD20 related diseases.

Description

Humanized monoclonal antibody for resisting CD20 and preparation thereof

Technical Field

The invention relates to the field of medicines, in particular to a humanized monoclonal antibody resisting CD20 and a preparation thereof.

Background

The humanized antibody is characterized in that a murine component is further reduced on the basis of a chimeric antibody, a murine anti-CDR region is reserved, other parts of the humanized antibody are partially replaced by a human antibody, the humanized antibody is superior to the murine antibody in disease treatment because the reduction of the murine component in the antibody can reduce immunological rejection of the body, and the humanized antibody has the other advantages that the half life period in vivo is long, the half life period of the murine antibody is less than one day, and the humanized antibody can reach days and sometimes even longer.

Clinical treatment of murine mabs is limited because they elicit human anti-mouse antibody responses (HAMA) in clinical treatment.

Thus, there remains a need in the art to develop anti-CD 20 humanized antibodies suitable for treating patients.

Disclosure of Invention

The invention aims to carry out humanized design and expression on a murine CD20 antibody (Rituximab), obtain a humanized antibody with the affinity of one order of magnitude with the murine antibody, and reduce the possible immunogenicity of the murine antibody in a human body to the maximum extent.

The invention also aims to provide a high-affinity high-bioactivity CD20 humanized antibody and application thereof.

In a first aspect of the invention, there is provided an antibody heavy chain variable region comprising the following three complementarity determining regions CDRs:

CDR1 shown in SEQ ID NO.1,

CDR2 shown in SEQ ID NO. 2, and

CDR3 shown in SEQ ID NO. 3,

and the affinity of the heavy chain variable region is one order of magnitude with that of the heavy chain variable region shown in the murine SEQ ID NO. 7.

In another preferred embodiment, the heavy chain variable region is mutated at one or more amino acids corresponding to the sequence shown in SEQ ID No.7 selected from the group consisting of:

glutamine (Q) at position 5, proline (P) at position 7, leucine (L) at position 11, valine (V) at position 12, methionine (M) at position 20, lysine (K) at position 38, arginine (R) at position 43, isoleucine (I) at position 48, lysine (K) at position 67, alanine (a) at position 68, leucine (L) at position 70, lysine (K) at position 74, serine (S) at position 76, alanine (a) at position 79, glutamine (Q) at position 82, threonine (T) at position 87, serine (S) at position 91, and alanine (a) at position 113.

In another preferred embodiment, the mutation of the heavy chain variable region corresponding to the sequence shown in SEQ ID No.7 is selected from the group consisting of:

Q5V, P7S, L11V, V12K, M20V, K38R, R43Q, I48M, K67R, a68V, L70M, L70I, K74T, S76T, S76A, a79V, Q82E, T87R, S91T, a113Q, or a combination thereof.

In another preferred embodiment, the heavy chain variable region is further mutated at an amino acid corresponding to the sequence shown in SEQ ID No.7 selected from the group consisting of:

glycine (G) at position 44.

In another preferred embodiment, the mutation in the heavy chain variable region corresponding to the sequence shown in SEQ ID No.7 is further selected from the group consisting of:

G44R。

in another preferred embodiment, the heavy chain variable region is selected from the group consisting of:

(1) a heavy chain variable region having a sequence as shown in SEQ ID No.9 or 11;

(2) a heavy chain variable region derived from the sequence of SEQ ID No.9 or 11 having the function of the heavy chain variable region of (1) by substituting, deleting, modifying and/or adding at least one (e.g., 1 to 20, preferably 1 to 15, more preferably 1 to 10, more preferably 1 to 8, more preferably 1 to 3, most preferably 1 or 2) amino acid residues in the amino acid sequence of SEQ ID No.9 or 11.

In another preferred embodiment, the heavy chain variable region may be mutated in one or more (1-20, preferably 1-15, more preferably 1-10, more preferably 1-8, more preferably 1-3, most preferably 1 or 2) amino acids in the framework region corresponding to the sequence shown in SEQ ID No.9 or 11.

In another preferred embodiment, the heavy chain variable region has the sequence shown in SEQ ID NO.9 or 11.

In a second aspect, the present invention provides an antibody heavy chain having a heavy chain variable region as described in the first aspect of the invention.

In another preferred embodiment, the heavy chain of said antibody further comprises a heavy chain constant region.

In another preferred embodiment, the heavy chain constant region is of human, murine or rabbit origin, preferably of human origin.

In a third aspect, the present invention provides an antibody light chain variable region comprising the following three complementarity determining regions CDRs:

CDR1 shown in SEQ ID NO. 4,

CDR2 shown in SEQ ID NO. 5, and

CDR3 shown in SEQ ID NO. 6,

and the affinity of the light chain variable region is one order of magnitude with that of the light chain variable region shown in the murine SEQ ID NO. 8.

In another preferred embodiment, the light chain variable region is mutated at one or more amino acids corresponding to the sequence shown in SEQ ID No.8 selected from the group consisting of:

glutamine (Q) at position 1, valine (V) at position 3, serine (S) at position 5, alanine (a) at position 9, isoleucine (I) at position 10, proline (P) at position 15, glutamic acid (E) at position 17, lysine (K) at position 18, methionine (M) at position 21, phenylalanine (F) at position 35, serine (S) at position 41, serine (S) at position 42, proline (P) at position 45, tryptophan (W) at position 46, valine (V) at position 59, tyrosine (Y) at position 70, serine (S) at position 71, arginine (R) at position 76, valine (V) at position 77, alanine (a) at position 82, and leucine (L) at position 103.

In another preferred embodiment, the mutation of the light chain variable region corresponding to the sequence shown in SEQ ID No.8 is selected from the group consisting of:

Q1D, V3Q, S5T, A9S, I10F, P15V, E17D, K18R, M21I, F35Y, S41K, S42A, P45L, W46L, V59S, Y70F, S71T, R76S, V77L, a82F, L103V, or a combination thereof.

In another preferred embodiment, the light chain variable region is selected from the group consisting of:

(1) a light chain variable region with a sequence shown as SEQ ID NO. 10;

(2) a light chain variable region derived from the sequence shown in SEQ ID No.10, which has the function of the light chain variable region shown in (1), formed by substituting, deleting, modifying and/or adding at least one (e.g., 1-20, preferably 1-15, more preferably 1-10, more preferably 1-8, more preferably 1-3, most preferably 1 or 2) amino acid residues in the amino acid sequence shown in SEQ ID No. 10.

In another preferred embodiment, the light chain variable region may be mutated in one or more (1-20, preferably 1-15, more preferably 1-10, more preferably 1-8, more preferably 1-3, most preferably 1 or 2) amino acids in the framework region corresponding to the sequence shown in SEQ ID No. 10.

In another preferred embodiment, the light chain variable region has the sequence shown in SEQ ID No. 10.

In a fourth aspect, the present invention provides a light chain of an antibody, said light chain having a light chain variable region as described in the third aspect of the invention.

In another preferred embodiment, the light chain of the antibody further comprises a light chain constant region.

In another preferred embodiment, the light chain constant region is of human, murine or rabbit origin, preferably of human origin.

In a fifth aspect, the invention provides an antibody having:

(1) a heavy chain variable region according to the first aspect of the invention; and/or

(2) A light chain variable region according to the third aspect of the invention;

in another preferred embodiment, the antibody has: a heavy chain according to the second aspect of the invention; and/or a light chain according to the fourth aspect of the invention.

In another preferred embodiment, the antibody has a heavy chain variable region as shown in SEQ ID No.9 or 11; and/or the light chain variable region as shown in SEQ ID NO. 10.

In another preferred embodiment, the light chain variable region sequence of the antibody is shown as SEQ ID NO. 10; and/or the heavy chain variable region sequence of the antibody is shown as SEQ ID NO.9 or 11.

In another preferred embodiment, the light chain variable region sequence of the antibody is shown as SEQ ID NO. 10; and the heavy chain variable region sequence of the antibody is shown as SEQ ID NO. 9.

In another preferred embodiment, the antibody has a light chain variable region as shown in SEQ ID No. 10; and the antibody has a heavy chain variable region with a sequence shown as SEQ ID NO. 11.

In another preferred embodiment, the antibody is a humanized antibody.

In another preferred embodiment, the antibody specifically binds to CD 20.

In another preferred embodiment, the antibody is a double-chain antibody or a single-chain antibody.

In another preferred embodiment, the antibody is a monoclonal antibody.

In another preferred embodiment, the antibody is a bispecific antibody.

In another preferred embodiment, the antibody is in the form of a drug conjugate.

In a sixth aspect, the present invention provides a recombinant protein having:

(i) a heavy chain variable region according to the first aspect of the invention, a heavy chain according to the second aspect of the invention, a light chain variable region according to the third aspect of the invention, a light chain according to the fourth aspect of the invention, or an antibody according to the fifth aspect of the invention; and

(ii) optionally a tag sequence to facilitate expression and/or purification.

In another preferred embodiment, the tag sequence comprises a 6His tag.

In another preferred embodiment, the recombinant protein (or polypeptide) comprises a fusion protein.

In another preferred embodiment, the recombinant protein is a monomer, dimer, or multimer.

The seventh aspect of the present invention provides an antibody preparation comprising:

(a) an antibody according to the fifth aspect of the invention; and

(b) a vector, said vector comprising: a buffer, sterile water, and optionally a surfactant.

In an eighth aspect, the present invention provides a kit comprising an antibody preparation according to the seventh aspect of the present invention, and a container for holding the antibody preparation.

In a ninth aspect, the invention provides a CAR construct wherein the scFv segment of the antigen binding region of the CAR construct is a binding region that specifically binds to CD20 and has a heavy chain variable region according to the first aspect of the invention and a light chain variable region according to the third aspect of the invention.

In a tenth aspect, the invention provides a recombinant immune cell expressing an exogenous CAR construct according to the ninth aspect of the invention.

In another preferred embodiment, the immune cell is selected from the group consisting of: NK cells, T cells.

In another preferred embodiment, the immune cell is from a human or non-human mammal (e.g., a mouse).

The eleventh aspect of the present invention provides an antibody drug conjugate, comprising:

(a) an antibody moiety selected from the group consisting of: a heavy chain variable region according to the first aspect of the invention, a heavy chain according to the second aspect of the invention, a light chain variable region according to the third aspect of the invention, a light chain according to the fourth aspect of the invention, or an antibody according to the fifth aspect of the invention, or a combination thereof; and

(b) a coupling moiety coupled to the antibody moiety, the coupling moiety selected from the group consisting of: a detectable label, a drug, a toxin, a cytokine, a radionuclide, an enzyme, or a combination thereof.

In another preferred embodiment, said antibody moiety is coupled to said coupling moiety by a chemical bond or a linker.

In a twelfth aspect, the present invention provides the use of an active ingredient selected from the group consisting of: the heavy chain variable region according to the first aspect of the invention, the heavy chain according to the second aspect of the invention, the light chain variable region according to the third aspect of the invention, the light chain according to the fourth aspect of the invention, or the antibody according to the fifth aspect of the invention, the recombinant protein according to the sixth aspect of the invention, the immune cell according to the tenth aspect of the invention, the antibody drug conjugate according to the eleventh aspect of the invention, or a combination thereof, wherein the active ingredient is for use in the administration of a therapeutically effective amount of the active agent

(a) Preparing a detection reagent or a kit;

(b) preparing a medicament or preparation for preventing and/or treating CD20 related diseases; and/or

(c) Preparing a medicament or a preparation for preventing and/or treating cancer or tumor.

In another preferred embodiment, the tumor is selected from the group consisting of: a hematologic tumor, a solid tumor, or a combination thereof.

In another preferred embodiment, the hematological tumor is selected from the group consisting of: acute Myeloid Leukemia (AML), Multiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL), Acute Lymphocytic Leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), Hodgkin's lymphoma, or a combination thereof. In another preferred embodiment, the solid tumor is selected from the group consisting of: gastric cancer, gastric cancer peritoneal metastasis, liver cancer, leukemia, kidney tumor, lung cancer, small intestine cancer, bone cancer, prostate cancer, colorectal cancer, breast cancer, large intestine cancer, cervical cancer, ovarian cancer, lymph cancer, nasopharyngeal cancer, adrenal gland tumor, bladder tumor, non-small cell lung cancer (NSCLC), brain glioma, endometrial cancer, or a combination thereof.

In another preferred embodiment, the tumor is a tumor highly expressing CD 20.

In another preferred embodiment, the medicament or preparation is used for preparing a medicament or preparation for preventing and/or treating diseases related to CD20 (positive expression).

In another preferred embodiment, the antibody is in the form of A Drug Conjugate (ADC).

In another preferred embodiment, the detection reagent or the kit is used for diagnosing CD20 related diseases.

In another preferred embodiment, the detection reagent or kit is used for detecting CD20 protein in a sample.

In another preferred embodiment, the detection reagent is a detection sheet.

In a thirteenth aspect, the present invention provides a pharmaceutical composition comprising:

(i) an active ingredient selected from the group consisting of: a heavy chain variable region according to the first aspect of the invention, a heavy chain according to the second aspect of the invention, a light chain variable region according to the third aspect of the invention, a light chain according to the fourth aspect of the invention, or an antibody according to the fifth aspect of the invention, a recombinant protein according to the sixth aspect of the invention, an immune cell according to the tenth aspect of the invention, an antibody drug conjugate according to the eleventh aspect of the invention, or a combination thereof; and

(ii) a pharmaceutically acceptable carrier, diluent or excipient.

In another preferred embodiment, the pharmaceutical composition is a liquid preparation.

In another preferred embodiment, the pharmaceutical composition is an injection.

In another preferred embodiment, the concentration of the cells in the pharmaceutical composition is 1 × 10³-1×10⁹Individual cells/ml, preferably 1X 10⁵-1×10⁸Individual cells/ml.

In another preferred embodiment, the pharmaceutical composition further comprises other drugs (such as nucleic acid drugs, antibody drugs, targeting drugs, other immune cell drugs, other CAR-T drugs, chemotherapeutic drugs, or combinations thereof) that selectively kill tumor cells.

In another preferred embodiment, the pharmaceutical composition is used for treating tumors.

In another preferred embodiment, the tumor is a tumor highly expressing CD 20.

In a fourteenth aspect, the present invention provides a polynucleotide encoding a polypeptide selected from the group consisting of:

(1) a heavy chain variable region according to the first aspect of the invention, a heavy chain according to the second aspect of the invention, a light chain variable region according to the third aspect of the invention, a light chain according to the fourth aspect of the invention, or an antibody according to the fifth aspect of the invention; or

(2) A recombinant protein according to the sixth aspect of the invention;

(3) a CAR construct according to the ninth aspect of the invention.

In a fifteenth aspect, the present invention provides a vector comprising a polynucleotide according to the fourteenth aspect of the present invention.

In another preferred embodiment, the carrier comprises: bacterial plasmids, bacteriophages, yeast plasmids, plant cell viruses, mammalian cell viruses such as adenoviruses, retroviruses, or other vectors.

In a sixteenth aspect, the present invention provides a genetically engineered host cell comprising a vector according to the fifteenth aspect of the invention or having integrated into its genome a polynucleotide according to the fourteenth aspect of the invention.

In a seventeenth aspect, the invention provides a method of preparing an engineered immune cell, comprising the steps of:

(A) providing an immune cell to be modified; and

(B) introducing a first expression cassette into the immune cell to be engineered, wherein the first expression cassette expresses a CAR construct according to the ninth aspect of the invention, thereby obtaining an engineered immune cell.

In another preferred embodiment, the first expression cassette comprises a nucleic acid sequence encoding a CAR construct according to the ninth aspect of the invention.

In another preferred embodiment, said first expression cassette is located on a vector or integrated into the chromosome of said engineered immune cell.

In another preferred embodiment, the carrier is selected from the group consisting of: DNA, RNA, plasmids, lentiviral vectors, adenoviral vectors, retroviral vectors, transposons, oncolytic viral vectors, other gene transfer systems, or combinations thereof.

In another preferred embodiment, the vector is a viral vector (e.g., a lentiviral vector).

In another preferred embodiment, the vector is a transposon vector.

In another preferred embodiment, the immune cell is a T cell or NK cell.

In another preferred embodiment, the method further comprises the step of performing functional and effective detection on the obtained engineered immune cells.

In an eighteenth aspect, the present invention provides a method for in vitro detection of CD20 protein in a sample, the method comprising the steps of:

(1) contacting said sample in vitro with an antibody according to the fifth aspect of the invention;

(2) detecting the formation of an antigen-antibody complex, wherein the formation of the complex is indicative of the presence of CD20 protein in the sample.

In another preferred embodiment, the method is non-diagnostic and non-therapeutic.

A nineteenth aspect of the present invention provides a detection panel, comprising: a substrate (support plate) and a test strip comprising an antibody according to the fifth aspect of the invention or an antibody drug conjugate according to the eleventh aspect of the invention.

A twentieth aspect of the present invention provides a kit comprising:

a first container, and a first nucleic acid sequence comprising a first expression cassette for expressing a CAR construct according to the ninth aspect of the invention, located within the first container.

A twenty-first aspect of the present invention provides a diagnostic kit comprising:

(1) a first container comprising an antibody according to the fifth aspect of the invention; and/or

(2) A second container comprising a secondary antibody directed against the antibody of the fifth aspect of the invention.

In another preferred embodiment, the kit comprises a test plate according to the nineteenth aspect of the present invention.

In a twenty-second aspect, the present invention provides a method for producing a recombinant polypeptide, the method comprising:

(a) culturing a host cell according to the sixteenth aspect of the invention under conditions suitable for expression;

(b) isolating a recombinant polypeptide from the culture, said recombinant polypeptide being an antibody according to the fifth aspect of the invention or a recombinant protein according to the sixth aspect of the invention.

In a twenty-third aspect, the present invention provides a method of treating a disease associated with CD20, the method comprising: administering to a subject in need thereof an antibody according to the fifth aspect of the invention, a recombinant protein according to the sixth aspect of the invention, a CAR construct according to the ninth aspect of the invention, an immune cell according to the tenth aspect of the invention, an antibody drug conjugate according to the eleventh aspect of the invention, a pharmaceutical composition according to the thirteenth aspect of the invention.

In another preferred example, the CD 20-associated disease comprises a CD 20-positive cancer or tumor.

It is to be understood that within the scope of the present invention, the above-described features of the present invention and those specifically described below (e.g., in the examples) may be combined with each other to form new or preferred embodiments. Not to be reiterated herein, but to the extent of space.

Drawings

Figure 1 shows different humanized whole antibody flow assays.

FIG. 2 shows an electrophoretogram of expression purification of the full antibody.

FIG. 3 shows an alignment of the humanized antibody NH2-1-NL2-1 with the heavy chain variable region of a murine antibody.

FIG. 4 shows an alignment of the humanized antibody NH2-1-NL2-1 with the murine antibody light chain variable region.

FIG. 5 shows an alignment of the humanized antibody NH1-1-NL2-1 with the heavy chain variable region of a murine antibody.

FIG. 6 shows an alignment of the humanized antibody NH1-1-NL2-1 with the murine antibody light chain variable region.

Fig. 7 shows a flow analysis of the binding of murine antibodies to Raji cells at different concentrations.

FIG. 8 shows a graph of flow analysis of the binding of varying concentrations of humanized NH1-1-NL2-1 antibody to Raji cells.

FIG. 9 shows a graph of flow analysis of the binding of varying concentrations of humanized NH2-1-NL2-1 antibody to Raji cells.

Fig. 10 shows a statistical plot of the mean fluorescence intensity of the binding of different concentrations of 3 antibodies to Raji cells.

Detailed Description

The present inventors have unexpectedly obtained an anti-CD 20 humanized antibody having excellent affinity and good structural stability through extensive and intensive studies and extensive screening. Specifically, the present invention humanizes the framework regions of a human antibody template. The humanized antibody reaches the affinity similar to that of the murine antibody, and is one order of magnitude.

Specifically, the invention carries out humanized design and modification on a murine CD20 antibody (Rituximab), expresses a corresponding humanized antibody, obtains 2 humanized antibody sequences with the same affinity as that of the murine antibody through flow verification and affinity verification, and further screens the humanized antibody sequences to finally screen a humanized antibody sequence (Ruhab-NL2-1-NH1-1) with the same affinity as that of the murine antibody and reaching one order of magnitude. The present invention has been completed based on this finding.

Term(s) for

In order that the invention may be more readily understood, certain technical and scientific terms are specifically defined below. Unless otherwise defined herein, all other technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

The three letter codes and the one letter codes for amino acids used in the present invention are as described in j. diol. chem,243, p3558 (1968).

As used herein, the terms "administration" and "treatment" refer to the application of an exogenous drug, therapeutic agent, diagnostic agent, or composition to an animal, human, subject, cell, tissue, organ, or biological fluid. "administration" and "treatment" may refer to therapeutic, pharmacokinetic, diagnostic, research, and experimental methods. The treatment of the cells comprises contacting the reagent with the cells, and contacting the reagent with a fluid, and contacting the fluid with the cells. "administering" and "treating" also mean treating in vitro and ex vivo by a reagent, a diagnostic, a binding composition, or by another cell. "treatment" when applied to a human, animal or study subject refers to therapeutic treatment, prophylactic or preventative measures, research, and diagnosis; including contact of an anti-CD 20 antibody with a human or animal, subject, cell, tissue, physiological compartment, or physiological fluid.

As used herein, the term "treatment" refers to the administration of a therapeutic agent, either internally or externally, to a patient having one or more symptoms of a disease for which the therapeutic agent is known to have a therapeutic effect, comprising any of the anti-CD 20 antibodies of the invention and compositions thereof. Typically, the therapeutic agent is administered to the patient in an amount effective to alleviate one or more symptoms of the disease (therapeutically effective amount).

As used herein, the term "optional" or "optionally" means that the subsequently described event or circumstance may, but need not, occur. For example, "optionally comprising 1-3 antibody heavy chain variable regions" means that the antibody heavy chain variable regions of a particular sequence may, but need not, be 1, 2 or 3.

"sequence identity" as referred to herein means the degree of identity between two nucleic acid or two amino acid sequences when optimally aligned and compared with appropriate mutations such as substitutions, insertions or deletions. The sequence identity between a sequence described in the present invention and a sequence with which it is identical may be at least 85%, 90% or 95%, preferably at least 95%. Non-limiting examples include 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%.

CD20

CD20 is expressed on the surface of B cells at various stages of developmental differentiation except plasma cells, and plays an important regulatory role in B cell proliferation and differentiation by directly acting on B cells through regulation of transmembrane calcium ion flux. The CD20 antigen is a B cell differentiation antigen, located only on pre-B cells and mature B cells, and is expressed in more than 95% of B cell lymphomas, but not in hematopoietic stem cells, plasma cells and other normal tissues. CD20 is therefore an ideal target for targeted therapy of B-cell lymphomas and leukemias.

Murine Rituximab variable region sequence information

Light chain variable region of murine Rituximab monoclonal antibody (SEQ ID NO.8)

QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKRTV

Heavy chain variable region of murine Rituximab monoclonal antibody (SEQ ID NO.7)

QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSA

Humanized NL2-1-NH1-1 variable region sequence information

Humanized monoclonal antibody NL2-1-NH1-1 light chain variable region (SEQ ID NO.10)

DIQLTQSPSFLSASVGDRVTITCRASSSVSYIHWYQQKPGKAPKLLIYATSNLASGVPSRFSGSGSGTSFTLTISSLQPEDFATYYCQQWTSNPPTFGGGTKVEIKRTV

Humanized monoclonal antibody NL2-1-NH1-1 heavy chain variable region (SEQ ID NO.9)

QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQTPGQRLEWMGAIYPGNGDTSYNQKFKGRVTITADTSASTAYMELSSLRSEDTAVYYCARSTYYGGDWYFNVWGQGTTVTVS

Humanized Ruhab-NL2-1-NH2-1 variable region sequence information

Humanized monoclonal antibody Ruhab-NL2-1-NH2-1 light chain variable region (SEQ ID NO.10)

Humanized monoclonal antibody Ruhab-NL2-1-NH2-1 heavy chain variable region (SEQ ID NO.11)

QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQTPGQGLEWMGAIYPGNGDTSYNQKFKGRVTMTADTSTSTVYMELSSLRSEDTAVYYCARSTYYGGDWYFNVWGQGTTVTVS

Antibodies

As used herein, the term "antibody" refers to an immunoglobulin, a tetrapeptide chain structure made up of two identical heavy chains and two identical light chains linked by interchain disulfide bonds. The constant regions of immunoglobulin heavy chains differ in their amino acid composition and arrangement, and thus, their antigenicity. Accordingly, immunoglobulins can be classified into five classes, otherwise known as the isotype of immunoglobulins, i.e., IgM, IgD, IgG, IgA, and IgE, with their corresponding heavy chains being the μ, δ, γ, α, and ε chains, respectively. The same class of Ig can be divided into different subclasses according to the difference of amino acid composition of the heavy chain region and the number and position of the disulfide bonds of the heavy chain, for example, IgG can be divided into IgG1, IgG2, IgG3 and IgG 4. Light chains are classified as either kappa or lambda depending on the constant region. Each of the five classes of Ig may have either a kappa chain or a lambda chain. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known to those skilled in the art.

The antibody light chain of the invention may further comprise a light chain constant region comprising a human or murine kappa, lambda chain or variant thereof.

In the present invention, the antibody heavy chain of the present invention may further comprise a heavy chain constant region comprising human or murine IgG1, IgG2, IgG3, IgG4, or variants thereof. The sequences of the antibody heavy and light chains, near the N-terminus, are widely varied by about 110 amino acids, the variable region (Fv region); the remaining amino acid sequence near the C-terminus is relatively stable and is a constant region. The variable regions include 3 hypervariable regions (HVRs) and 4 Framework Regions (FRs) which are relatively sequence conserved. The 3 hypervariable regions determine the specificity of the antibody, also known as Complementarity Determining Regions (CDRs). Each of the Light Chain Variable Region (LCVR) and Heavy Chain Variable Region (HCVR) consists of 3 CDR regions and 4 FR regions in the order FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4 from amino terminus to carboxy terminus. The 3 CDR regions of the light chain refer to LCDR1, LCDR2 and LCDR 3; the 3 CDR regions of the heavy chain are referred to as HCDR1, HCDR2 and HCDR 3.

The term "murine antibody" is used in the present invention as a monoclonal antibody against CD20 prepared according to the knowledge and skill in the art. Preparation is accomplished by injecting a subject with the CD20 antigen and then isolating hybridomas that express antibodies having the desired sequence or functional properties. In a preferred embodiment of the invention, the murine CD20 antibody or antigen binding fragment thereof may further comprise a light chain constant region of a murine kappa, lambda chain or variant thereof, or further comprise a heavy chain constant region of a murine IgG1, IgG2, IgG3 or variant thereof.

The term "chimeric antibody" is an antibody obtained by fusing a variable region of a murine antibody to a constant region of a human antibody, and can reduce an immune response induced by the murine antibody.

The term "humanized antibody", also known as CDR-grafted antibody (CDR), refers to an antibody produced by grafting murine CDR sequences into a human antibody variable region framework, i.e., a different type of human germline antibody framework sequence. The humanized antibody can overcome the heterogenous reaction induced by the chimeric antibody carrying a great deal of murine protein components. Such framework sequences can be obtained from public DNA databases or published references that include germline antibody gene sequences. To avoid reduced immunogenicity and reduced activity, the human antibody variable region framework sequences may be minimally back-mutated or back-mutated to retain activity.

The term "antigen-binding fragment of an antibody" (or simply "antibody fragment") refers to one or more fragments of an antibody that retain the ability to specifically bind an antigen (e.g., CD 20). It has been shown that fragments of full-length antibodies can be used to perform the antigen-binding function of the antibody. Examples of binding fragments encompassed within the term "antigen binding fragment of an antibody" include

(i) Fab fragments, monovalent fragments consisting of the VL, VH, CL and CH1 domains;

(ii)F(ab’)₂a fragment comprising a bivalent fragment of two Fab fragments connected by a disulfide bridge on the chain compare region;

(iii) an Fd fragment consisting of the VH and CH1 domains;

(iv) an Fv fragment consisting of the VH and VL domains of a single arm of an antibody.

Fv antibodies contain the variable regions of the antibody heavy chain, the variable regions of the light chain, but no constant regions, and have the smallest antibody fragment of the entire antigen binding site. Generally, Fv antibodies also comprise a polypeptide linker between the VH and VL domains and are capable of forming the structures required for antigen binding.

The term "CDR" refers to one of the 6 hypervariable regions within the variable domain of an antibody which primarily contributes to antigen binding. One of the most common definitions of the 6 CDRs is provided by Kabat E.A et al, (1991) Sequences of proteins of immunological interest, NIH Publication 91-3242).

The term "epitope" or "antigenic determinant" refers to a site on an antigen to which an immunoglobulin or antibody specifically binds (e.g., a specific site on the CD20 molecule). Epitopes typically comprise at least 3,4,5,6,7,8,9,10,11,12,13,14 or 15 contiguous or non-contiguous amino acids in a unique spatial conformation.

The terms "specific binding," "selective binding," "selectively binds," and "specifically binds" refer to the binding of an antibody to an epitope on a predetermined antigen. Typically, the antibody is administered at a rate of about less than 10^-7M, e.g. less than about 1O^-8M、1O^-9M or lO^-10M or less affinity (KD) binding.

The term "competes for binding" refers to an antibody that recognizes the same epitope (also referred to as an antigenic determinant) or a portion of the same epitope on the extracellular region of CD20 and binds to the antigen as a monoclonal antibody of the invention. An antibody that binds to the same epitope as a monoclonal antibody of the invention refers to an antibody that recognizes and binds to the amino acid sequence of CD20 recognized by a monoclonal antibody of the invention.

The term "KD" or "KD" refers to the dissociation equilibrium constant of a particular antibody-antigen interaction. Typically, the antibodies of the invention are present in an amount less than about 10^-7M, e.g. less than about 10^-8M、10^-9M or l0^-10Dissociation equilibrium constant (K) of M or lessD) Binds to CD 20.

As used herein, the term "antigenic determinant" refers to a three-dimensional spatial site on an antigen that is not contiguous and is recognized by an antibody or antigen-binding fragment of the invention.

The invention includes not only intact antibodies, but also fragments of antibodies with immunological activity or fusion proteins of antibodies with other sequences. Accordingly, the invention also includes fragments, derivatives and analogs of the antibodies.

In the present invention, antibodies include murine, chimeric, humanized or fully human antibodies prepared using techniques well known to those skilled in the art. Recombinant antibodies, such as chimeric and humanized monoclonal antibodies, including human and non-human portions, can be prepared using recombinant DNA techniques well known in the art.

As used herein, the term "monoclonal antibody" refers to an antibody secreted by a clone obtained from a single cell source. Monoclonal antibodies are highly specific, being directed against a single epitope. The cell may be a eukaryotic, prokaryotic, or phage clonal cell line.

In the present invention, the antibody may be monospecific, bispecific, trispecific, or more multispecific.

In the present invention, the antibody of the present invention also includes conservative variants thereof, which means that at most 10, preferably at most 8, more preferably at most 5, and most preferably at most 3 amino acids are replaced by amino acids having similar or similar properties as compared with the amino acid sequence of the antibody of the present invention to form a polypeptide. These conservative variant polypeptides are preferably generated by amino acid substitutions according to Table 1.

TABLE 1

Initial residue(s)	Representative substitutions	Preferred substitutions
			Ala(A)	Val；Leu；Ile	Val
Arg(R)	Lys；Gln；Asn	Lys
			Asn(N)	Gln；His；Lys；Arg	Gln
Asp(D)	Glu	Glu
			Cys(C)	Ser	Ser
Gln(Q)	Asn	Asn
			Glu(E)	Asp	Asp
Gly(G)	Pro；Ala	Ala
			His(H)	Asn；Gln；Lys；Arg	Arg
Ile(I)	Leu；Val；Met；Ala；Phe	Leu
			Leu(L)	Ile；Val；Met；Ala；Phe	Ile
Lys(K)	Arg；Gln；Asn	Arg
			Met(M)	Leu；Phe；Ile	Leu
Phe(F)	Leu；Val；Ile；Ala；Tyr	Leu
			Pro(P)	Ala	Ala
Ser(S)	Thr	Thr
			Thr(T)	Ser	Ser
Trp(W)	Tyr；Phe	Tyr
			Tyr(Y)	Trp；Phe；Thr；Ser	Phe
Val(V)	Ile；Leu；Met；Phe；Ala	Leu

anti-CD 20 humanized antibodies

The present invention provides an anti-CD 20 humanized antibody (hereinafter referred to as CD20 antibody). Specifically, the present invention provides a highly specific and high affinity humanized antibody against CD20 comprising a heavy chain variable region (VH) amino acid sequence and a light chain comprising a light chain variable region (VL) amino acid sequence.

In 1986, Jones et al firstly transplanted the heavy chain CDR of the murine monoclonal antibody to the framework region of the heavy chain of the human antibody, and then assembled with the light chain of the murine monoclonal antibody into a complete antibody and kept the affinity similar to that of the original murine monoclonal antibody, thereby providing a thought for the development of antibody humanization technology. Queen et al succeeded in constructing a humanized antibody against CD25 in 1989 by a CDR grafting method in which a human antibody Eu framework region was humanized and amino acids of a murine antibody were retained at partial sites of the framework region to maintain affinity. In 1992 Presta et al reported a successful humanization method by CDR grafting using human antibody subgroup consensus (consensus sequence) as a template. Pedersen et al, 1994, reported humanization of antibodies using surface remodeling (resurfacing). Hsiao et al, 1994, reported humanization methods for CDR grafting with human antibody Germine sequence framework regions. Jespers et al succeeded in constructing a humanization method by a method using a phage library (Shuffling library) in 1994.

The choice of human framework regions in antibody humanization is generally two, one is a known mature antibody and one is a human Germline sequence. Known mature antibody framework regions often contain somatic mutation sites that may confer potential immunogenicity. Compared with a mature antibody, the human Germline sequence framework region is theoretically lower in immunogenicity, more flexible in structure and strong in plasticity, and can easily accept different CDR regions. The use frequency of the human antibody Germinine gene in a human body has certain bias, and the humanized antibody of the Germinine framework region with high use frequency has the advantages of low immunogenicity, high expression quantity, stable structure and the like, so that the Germinine sequence with the highest similarity to the murine antibody is not selected in the process of humanization, the similarity and the use frequency of the human body are considered, and the framework region of Rituximab is selected for humanization through a large number of experimental screens. The invention selects the human antibody Germline framework region for CDR transplantation, so that the constructed humanized antibody has more stable structure, high expression quantity, low immunogenicity and higher druggability.

Specifically, as described in the first to fifth aspects of the present invention:

Humanized Ruhab-NL2-1-NH2-1 variable region sequence information

In another preferred embodiment, the sequence formed by adding, deleting, modifying and/or substituting at least one amino acid sequence is preferably an amino acid sequence with homology of at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95%.

The antibody of the present invention may be a double-chain or single-chain antibody, and may preferably be a fully humanized antibody.

The antibody derivatives of the present invention may be single chain antibodies, and/or antibody fragments, such as: fab, Fab ', (Fab')₂Or other known antibody derivatives in the art, and any one or more of IgA, IgD, IgE, IgG, and IgM antibodies or antibodies of other subtypes.

The antibodies of the invention may be humanized antibodies, CDR grafted and/or modified antibodies targeting CD 20.

In the above-mentioned aspect of the present invention, the number of amino acids to be added, deleted, modified and/or substituted is preferably not more than 40%, more preferably not more than 35%, more preferably 1 to 33%, more preferably 5 to 30%, more preferably 10 to 25%, and more preferably 15 to 20% of the total number of amino acids in the original amino acid sequence.

The invention successfully carries out humanization transformation on the CD20 mouse monoclonal antibody, the humanized antibody reaches the affinity (up to an order of magnitude) similar to that of a chimeric antibody, preliminary research on the solubility and endogenous fluorescence of the humanized antibody proves that the humanized antibody has preliminary druggability, and the humanized monoclonal antibody can be further developed into a humanized monoclonal antibody medicament for targeted therapy in the future.

In the present invention, the CDR1, CDR2 and CDR3 of the heavy chain variable region or the light chain variable region of the humanized antibody of the present invention are shown at the horizontal line in fig. 3 to 6, respectively.

Preparation of antibodies

Any method suitable for producing monoclonal antibodies may be used to produce the CD20 antibodies of the invention. For example, an animal may be immunized with a linked or naturally occurring CD20 protein or fragment thereof. Suitable immunization methods, including adjuvants, immunostimulants, repeated booster immunizations, and one or more routes may be used.

Any suitable form of CD20 may be used as an immunogen (antigen) for the production of non-human antibodies specific for CD20, which antibodies are screened for biological activity. The immunogen may be used alone or in combination with one or more immunogenicity enhancing agents known in the art. Immunogens can be purified from natural sources or produced in genetically modified cells. The DNA encoding the immunogen may be genomic or non-genomic in origin (e.g., cDNA). DNA encoding the immunogen may be expressed using suitable genetic vectors including, but not limited to, adenoviral vectors, baculovirus vectors, plasmids and non-viral vectors.

Humanized antibodies may be selected from any class of immunoglobulins, including IgM, IgD, IgG, IgA, and IgE. Likewise, any type of light chain can be used in the compounds and methods herein. In particular, kappa, lambda chains or variants thereof are useful in the compounds and methods of the invention.

An exemplary method of humanizing a CD20 antibody of the invention is described in example 1.

The sequence of the DNA molecule of the antibody or fragment thereof of the present invention can be obtained by a conventional technique, for example, by PCR amplification or genomic library screening. Alternatively, the coding sequences for the light and heavy chains may be fused together to form a single chain antibody.

Once the sequence of interest has been obtained, it can be obtained in large quantities by recombinant methods. This is usually done by cloning it into a vector, transferring it into a cell, and isolating the relevant sequence from the propagated host cell by conventional methods.

In addition, the sequence can be synthesized by artificial synthesis, especially when the fragment length is short. Generally, fragments with long sequences are obtained by first synthesizing a plurality of small fragments and then ligating them. The DNA sequence may then be introduced into various existing DNA molecules (or vectors, for example) and cells known in the art.

The term "nucleic acid molecule" refers to both DNA molecules and RNA molecules. The nucleic acid molecule may be single-stranded or double-stranded, but is preferably double-stranded DNA. A nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the coding sequence.

The term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. In one embodiment, the vector is a "plasmid," which refers to a circular double-stranded DNA loop into which additional DNA segments can be ligated.

The invention also relates to a vector comprising a suitable DNA sequence as described above and a suitable promoter or control sequence. These vectors may be used to transform an appropriate host cell so that it can express the protein.

The term "host cell" refers to a cell into which an expression vector has been introduced. The host cell may be a prokaryotic cell, such as a bacterial cell; or lower eukaryotic cells, such as yeast cells; or a higher eukaryotic cell, such as a plant or animal cell (e.g., a mammalian cell).

The steps described in the present invention for transforming a host cell with a recombinant DNA can be performed using techniques well known in the art. The obtained transformant can be cultured by a conventional method, and the transformant expresses the polypeptide encoded by the gene of the present invention. Depending on the host cell used, it is cultured in a conventional medium under suitable conditions.

Typically, the transformed host cells are cultured under conditions suitable for expression of the antibodies of the invention. The antibody of the invention is then purified by conventional immunoglobulin purification procedures, such as protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, ion exchange chromatography, hydrophobic chromatography, molecular sieve chromatography or affinity chromatography, using conventional separation and purification means well known to those skilled in the art.

The resulting monoclonal antibodies can be identified by conventional means. For example, the binding specificity of a monoclonal antibody can be determined by immunoprecipitation or by an in vitro binding assay, such as Radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA).

Antibody formulations

The antibody has different stability in different preparation buffers, and is represented by the change of charge heterogeneity, degradation, polymerization and the like of antibody molecules, and the change of the quality properties is related to the physicochemical properties of the antibody, so that the preparation buffers suitable for the antibody need to be screened according to the physicochemical properties of different antibodies in the development process of antibody drugs. The currently commonly used antibody preparation buffer systems include phosphate buffer, citric acid buffer, histidine buffer, and the like, and according to the antibody properties, saline ions with different concentrations or excipients such as sorbitol, trehalose, sucrose, and the like, and a proper amount of surfactants such as tween 20 or tween 80 and the like are added to maintain the stability of the antibody.

The antibody preparation of the invention is as described in the seventh aspect of the invention.

The antibody drug combination preparation can effectively inhibit side reactions such as aggregation precipitation, hydrolysis, oxidation, deamidation and the like of the humanized antibody, and can effectively improve the stability of the product under the conditions of pressurization (high temperature, strong light irradiation, freeze thawing and the like), acceleration and long-term refrigeration.

Pharmaceutical composition

The invention also provides a composition. In a preferred embodiment, the composition is a pharmaceutical composition comprising an antibody or an active fragment thereof or a fusion protein thereof or an ADC thereof or a corresponding CAR-T cell as described above, and a pharmaceutically acceptable carrier. Generally, these materials will be formulated in a non-toxic, inert and pharmaceutically acceptable aqueous carrier medium, wherein the pH is generally from about 5 to about 8, preferably from about 6 to about 8, although the pH will vary depending on the nature of the material being formulated and the condition being treated. The formulated pharmaceutical compositions may be administered by conventional routes including, but not limited to: intratumoral, intraperitoneal, intravenous, or topical administration.

The antibody of the present invention may also be used for cell therapy by intracellular expression of a nucleotide sequence, for example, for chimeric antigen receptor T cell immunotherapy (CAR-T) and the like.

The pharmaceutical composition of the invention can be directly used for binding CD20 protein molecules, and thus can be used for preventing and treating CD20 related diseases. In addition, other therapeutic agents may also be used simultaneously.

The pharmaceutical composition of the present invention comprises a safe and effective amount (e.g., 0.001-99 wt%, preferably 0.01-90 wt%, more preferably 0.1-80 wt%) of the monoclonal antibody (or conjugate thereof) of the present invention as described above and a pharmaceutically acceptable carrier or excipient. Such vectors include (but are not limited to): saline, buffer, glucose, water, glycerol, ethanol, and combinations thereof. The pharmaceutical preparation should be compatible with the mode of administration. The pharmaceutical composition of the present invention can be prepared in the form of an injection, for example, by a conventional method using physiological saline or an aqueous solution containing glucose and other adjuvants. Pharmaceutical compositions such as injections, solutions are preferably manufactured under sterile conditions. The amount of active ingredient administered is a therapeutically effective amount, for example from about 1 microgram per kilogram of body weight to about 5 milligrams per kilogram of body weight per day. In addition, the polypeptides of the invention may also be used with other therapeutic agents.

Where a pharmaceutical composition is used, a safe and effective amount of the pharmaceutical composition is administered to the mammal, wherein the safe and effective amount is generally at least about 10 micrograms/kg body weight, and in most cases does not exceed about 50 mg/kg body weight, preferably the dose is from about 10 micrograms/kg body weight to about 20 mg/kg body weight. Of course, the particular dosage will depend upon such factors as the route of administration, the health of the patient, and the like, and is within the skill of the skilled practitioner.

Detection use and kit

The antibodies of the invention are useful in detection applications, for example, for detecting a sample, thereby providing diagnostic information.

In the present invention, the specimen (sample) used includes cells, tissue samples and biopsy specimens. The term "biopsy" as used herein shall include all kinds of biopsies known to the person skilled in the art. Thus, a biopsy as used in the present invention may comprise a tissue sample prepared, for example, by endoscopic methods or by needle or needle biopsy of an organ.

Samples for use in the present invention include fixed or preserved cell or tissue samples.

The invention also provides a kit containing the antibody (or fragment thereof) of the invention, and in a preferred embodiment of the invention, the kit further comprises a container, instructions for use, a buffer, and the like. In a preferred embodiment, the antibody of the present invention may be immobilized on a detection plate.

The main advantages of the invention

(1) The invention develops a humanized CD20 antibody with the affinity reaching one order of magnitude of the murine antibody for the first time.

(2) The invention obtains a humanized CD20 antibody sequence for the first time.

(3) The humanized antibody of the invention can reduce the immunological rejection of the murine CD20 antibody in human body.

The invention will be further illustrated with reference to the following specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. Experimental procedures without specific conditions noted in the following examples, generally followed by conventional conditions, such as Sambrook et al, molecular cloning: the conditions described in the Laboratory Manual (New York: Cold Spring Harbor Laboratory Press,1989), or according to the manufacturer's recommendations. Unless otherwise indicated, percentages and parts are percentages and parts by weight.

Experiments in which specific conditions are not specified in the examples or test examples of the present invention are usually performed under conventional conditions or under conditions recommended by the manufacturers of raw materials/goods; reagents of specific sources are not indicated, and conventional reagents are purchased in the market.

Example 1

Firstly, an experimental step 1 and humanization design

Humanized design is carried out according to amino acid sequence information (Rituximab) of heavy chain and light chain of CD20 antibody, the CDR region sequence of the original antibody is kept unchanged, different humanized antibody templates are respectively selected for the heavy chain and the light chain according to the germline alignment result and the antibody structure simulation result, and back mutation is carried out on the framework region after humanization, so as to design the following candidate humanized antibody sequences.

Humanized candidate antibody amino acid sequence information:

>NH1

QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQTPGQRLEWMGAIYPGNGDTSYNQKFKGRVTITRDTSASTAYMELSSLRSEDTAVYYCARSTYYGGDWYFNVWGQGTTVTVS(SEQ ID NO.:12)

>NH1-1

QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQTPGQRLEWMGAIYPGNGDTSYNQKFKGRVTITADTSASTAYMELSSLRSEDTAVYYCARSTYYGGDWYFNVWGQGTTVTVS(SEQ ID NO.:9)

>NH2

QVQLVQSGAEVKKPGASVKVSCKASGYTFTYNMHWVRQTPGQGLEWMGAIYPGNGDTSYNQKFKGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARSTYYGGDWYFNVWGQGTTVTVS(SEQ ID NO.:13)

>NH2-1

QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQTPGQGLEWMGAIYPGNGDTSYNQKFKGRVTMTADTSTSTVYMELSSLRSEDTAVYYCARSTYYGGDWYFNVWGQGTTVTVS(SEQ ID NO.:11)

>NH3

QVQLVQSGAEVKKPGASVKVSCKVSGYTFTSYNMHWVRQAPGKGLEWMGAIYPGNGDTSYNQKFKGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATSTYYGGDWYFNVWGQGTTVTVS(SEQ ID NO.:14)

>NH3-1

QVQLVQSGAEVKKPGASVKVSCKVSGYTFTSYNMHWVRQTPGKGLEWMGAIYPGNGDTSYNQKFKGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATSTYYGGDWYFNVWGQGTTVTVS(SEQ ID NO.:15)

>NL2-1

DIQLTQSPSFLSASVGDRVTITCRASSSVSYIHWYQQKPGKAPKLLIYATSNLASGVPSRFSGSGSGTSFTLTISSLQPEDFATYYCQQWTSNPPTFGGGTKVEIKRTV(SEQ ID NO.:10)

>NL3

EIVLTQSPATLSLSPGERATLSCRASSSVSYIHWYQQKPGQAPRLLIYATSNLASGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQWTSNPPTFGGGTKVEIKRTV(SEQ ID NO.:16)

the corresponding nucleic acid coding sequence information is as follows:

>NH1

CAGGTTCAGCTGGTTCAGTCTGGCGCCGAAGTGAAGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGCGGCTACACCTTTACCAGCTACAACATGCACTGGGTCCGACAGACCCCTGGCCAGAGACTTGAATGGATGGGCGCCATCTATCCCGGCAACGGCGACACCTCCTACAACCAGAAATTCAAGGGCCGCGTGACCATCACCAGAGACACATCTGCCAGCACCGCCTACATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGTGCCAGAAGCACCTACTACGGCGGCGACTGGTACTTCAATGTGTGGGGCCAGGGCACCACCGTGACAGTTTCT(SEQ ID NO.:17)

>NH1-1

CAGGTTCAGCTGGTTCAGTCTGGCGCCGAAGTGAAGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGCGGCTACACCTTTACCAGCTACAACATGCACTGGGTCCGACAGACCCCTGGCCAGAGACTTGAATGGATGGGCGCCATCTATCCCGGCAACGGCGACACCTCCTACAACCAGAAATTCAAGGGCAGAGTGACCATCACCGCCGACACATCTGCCAGCACCGCCTACATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGTGCCAGAAGCACCTACTACGGCGGCGACTGGTACTTCAATGTGTGGGGCCAGGGCACCACCGTGACAGTTTCT(SEQ ID NO.:18)

>NH2

CAGGTTCAGCTGGTTCAGTCTGGCGCCGAAGTGAAGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGCGGCTACACCTTTACCTACAACATGCACTGGGTCCGACAGACCCCTGGACAGGGACTTGAATGGATGGGCGCCATCTATCCCGGCAACGGCGACACCAGCTACAACCAGAAATTCAAGGGCCGCGTGACCATGACCAGAGACACCAGCACCTCCACCGTGTACATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGTGCCAGAAGCACCTACTACGGCGGCGACTGGTACTTCAATGTGTGGGGCCAGGGCACCACCGTGACAGTTTCT(SEQ ID NO.:19)

>NH2-1

CAGGTTCAGCTGGTTCAGTCTGGCGCCGAAGTGAAGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGCGGCTACACCTTTACCAGCTACAACATGCACTGGGTCCGACAGACACCTGGACAGGGACTCGAATGGATGGGCGCCATCTATCCCGGCAATGGCGACACCTCCTACAACCAGAAATTCAAGGGCAGAGTGACCATGACCGCCGACACCAGCACAAGCACCGTGTACATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTACTGTGCCAGAAGCACCTACTACGGCGGCGACTGGTACTTCAATGTGTGGGGCCAGGGCACCACCGTGACAGTTTCT(SEQ ID NO.:20)

>NH3

CAGGTTCAGCTGGTTCAGTCTGGCGCCGAAGTGAAGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGTGTCCGGCTACACCTTTACCAGCTACAACATGCACTGGGTCCGACAGGCCCCTGGCAAAGGACTTGAATGGATGGGCGCCATCTATCCCGGCAACGGCGACACCTCCTACAACCAGAAATTCAAGGGCAGAGTGACCATGACCGAGGACACCAGCACCGATACCGCCTACATGGAACTGAGCAGCCTGCGGAGCGAAGATACCGCCGTGTACTACTGTGCCACCTCCACCTACTATGGCGGCGACTGGTACTTCAACGTGTGGGGCCAGGGAACCACCGTGACAGTTTCT(SEQ ID NO.:21)

>NH3-1

CAGGTTCAGCTGGTTCAGTCTGGCGCCGAAGTGAAGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGTGTCCGGCTACACCTTTACCAGCTACAACATGCACTGGGTCCGACAGACCCCTGGCAAAGGCCTTGAATGGATGGGCGCCATCTATCCCGGCAACGGCGACACCTCCTACAACCAGAAATTCAAGGGCAGAGTGACCATGACCGAGGACACCAGCACCGATACCGCCTACATGGAACTGAGCAGCCTGCGGAGCGAAGATACCGCCGTGTACTACTGTGCCACCTCCACCTACTATGGCGGCGACTGGTACTTCAACGTGTGGGGCCAGGGAACCACCGTGACAGTTTCT(SEQ ID NO.:22)

>NL2-1

GACATCCAGCTGACCCAGTCTCCAAGCTTTCTGAGCGCCAGCGTGGGCGACAGAGTGACCATTACATGTAGAGCCAGCAGCAGCGTGTCCTACATCCACTGGTATCAGCAGAAGCCCGGCAAGGCCCCTAAGCTGCTGATCTACGCCACAAGCAATCTGGCCAGCGGCGTGCCAAGCAGATTTTCTGGCTCTGGCAGCGGCACCAGCTTCACCCTGACCATATCTAGCCTGCAGCCTGAGGACTTCGCCACCTACTACTGCCAGCAGTGGACCAGCAATCCTCCTACCTTTGGCGGAGGCACCAAGGTGGAAATCAAGCGGACAGTG(SEQ ID NO.:23)

>NL3

GAGATCGTGCTGACACAGTCTCCCGCCACACTGTCACTGTCTCCAGGCGAAAGAGCCACACTGAGCTGTAGAGCCAGCAGCAGCGTGTCCTACATCCACTGGTATCAGCAGAAGCCCGGACAGGCCCCTAGACTGCTGATCTACGCCACAAGCAATCTGGCCAGCGGCATCCCCGATAGATTTTCCGGCTCTGGCTCCGGCACCGACTTCACCCTGACAATCAGCAGACTGGAACCCGAGGACTTCGCCGTGTACTACTGCCAGCAGTGGACCAGCAATCCTCCTACCTTTGGCGGAGGCACCAAGGTGGAAATCAAGCGGACAGTG(SEQ ID NO.:24)

2. humanized antibody gene synthesis and expression vector construction

The heavy chain and the light chain of the humanized antibody designed above are subjected to gene synthesis respectively, the heavy chain is subcloned into a pcDNA3.1-IgG1Fc expression vector, and the light chain is subcloned into a pcDNA3.1-IgKc expression vector. After the vector was verified to be free of errors by sequencing, endotoxin-free plasmids were prepared using a Qiagen plasmid macrodrawer.

3. Humanized antibody expression and purification

3.1 the LVTransm transfection reagent and the single chain antibody expression vector are taken out from the refrigerator, thawed at room temperature, blown up and down by a pipette gun and mixed completely. Remove PBS or HBSS buffer and warm to room temperature. And adding 2mL of PBS into one hole of a 6-hole plate, respectively adding 65 mu g of pcDNA3.1-IgG1Fc and 65 mu g of pcDNA3.1-IgKc, blowing and beating the mixture up and down by a liquid transfer gun to be fully mixed, adding 400 mu L of LVTransm, immediately blowing and beating the mixture up and down by a liquid transfer gun to be mixed, and standing the mixture at room temperature for 10 minutes.

3.2 the DNA/LVTransm complex was added to 50mL of 293F-SVP16 cells, and mixed well by gentle shaking. Will be thinCulturing the cells in a 37 ℃ and 5% CO2 incubator at 130RPM for 6-8 hours, adding 50mL of fresh FreeStyle^TM293Expression Medium, and the cells were returned to the incubator to continue the culture.

3.3 after continuous culture for 7 days, the culture supernatant was collected by centrifugation, filtered through a 0.45 μm filter, and the filtrate was transferred to a sterile centrifuge tube to purify the single-chain antibody using a Protein A column.

4. Flow assay for binding of humanized antibodies to target proteins

4.1 resuscitate Raji cells from liquid nitrogen and use 1640, 10% FBS complete medium to adjust cell status to logarithmic growth phase.

4.2 dividing Raji cells into several parts, each part of cells number 1 x 10^6 cells, using 1mL PBS heavy suspension cells, respectively adding purified humanized full antibody, fully mixing, room temperature incubation for half an hour.

4.3800 Xg at room temperature for 5 minutes, remove the antibody containing supernatant, using PBS washing cells 3 times;

4.4 adding 2uL of Anti-human IgG marked by PE, fully and uniformly mixing, and incubating for 30min at room temperature in a dark place;

4.5800 Xg at room temperature for 5 minutes, remove the secondary antibody containing supernatant, use PBS washing cells 3 times;

4.6 resuspend cells using 500uL PBS and perform flow analysis.

Results of the experiment

1. Sequencing results of heavy chain and light chain expression vectors of humanized antibody

All constructed heavy and light chain expression vectors were Sanger sequenced and the sequencing results were consistent with the sequence of interest (sequence of the present invention).

2. Flow cytometry result of humanized full antibody

As a result: as shown in FIG. 1, according to the flow detection results, 2 humanized vectors (Ruhab-NL2-1-NH2-1 and Ruhab-NL2-1-NH1-1) with higher flow detection affinity were selected from different humanized antibodies for expression and purification of a large amount of whole antibodies.

3. Expression purification of full antibody

As shown in fig. 2, the results indicate that the humanized antibody is normally expressed at the protein level.

4. Alignment of sequences before and after antibody humanization

The results are shown in FIGS. 3,4,5, and 6, which are the heavy and light chain variable region alignments of two humanized antibodies with murine antibodies.

5. Purified antibody flow assay

The results of the Rumab antibody gradient dilution assay are shown in FIG. 7.

The results of the Ruhab-NL2-1-NH1-1 antibody gradient dilution assay are shown in FIG. 8.

The results of the Ruhab-NL2-1-NH2-1 antibody gradient dilution assay are shown in FIG. 9.

As shown in fig. 10, MFI represents mean fluorescence intensity, which is data obtained by flow measurement of the preparation.

And (4) analyzing results: according to the flow detection result, the affinity of the humanized antibody Ruhab-NL2-1-NH1-1 is consistent with that of the chimeric antibody Rumab, and can reach an order of magnitude.

The invention carries out humanized design and modification on a murine CD20 antibody (Rituximab), expresses a corresponding humanized antibody, and finally obtains 1 humanized antibody sequence (NL2-1-NH1-1) which has consistent affinity with the murine antibody and reaches one order of magnitude through flow verification and affinity verification.

All documents referred to herein are incorporated by reference into this application as if each were individually incorporated by reference. Furthermore, it should be understood that various changes and modifications of the present invention can be made by those skilled in the art after reading the above teachings of the present invention, and these equivalents also fall within the scope of the present invention as defined by the appended claims.

Sequence listing

<110> Bosheng Ji pharmaceutical technology (Suzhou) Co., Ltd

<120> anti-CD 20 humanized monoclonal antibody and preparation thereof

<130> P2018-2420

<160> 24

<170> SIPOSequenceListing 1.0

<210> 1

<211> 7

<212> PRT

<213> Artificial sequence (artificial sequence)

<400> 1

Gly Tyr Thr Phe Thr Ser Tyr

1 5

<210> 2

<211> 7

<212> PRT

<213> Artificial sequence (artificial sequence)

<400> 2

Tyr Pro Gly Asn Gly Asp Thr

1 5

<210> 3

<211> 11

<212> PRT

<213> Artificial sequence (artificial sequence)

<400> 3

Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe Asn

1 5 10

<210> 4

<211> 10

<212> PRT

<213> Artificial sequence (artificial sequence)

<400> 4

Arg Ala Ser Ser Ser Val Ser Tyr Ile His

1 5 10

<210> 5

<211> 8

<212> PRT

<213> Artificial sequence (artificial sequence)

<400> 5

Ala Thr Ser Asn Leu Ala Ser Gly

1 5

<210> 6

<211> 9

<212> PRT

<213> Artificial sequence (artificial sequence)

<400> 6

Gln Gln Trp Thr Ser Asn Pro Pro Thr

1 5

<210> 7

<211> 121

<212> PRT

<213> Artificial sequence (artificial sequence)

<400> 7

Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala

1 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr

20 25 30

Asn Met His Trp Val Lys Gln Thr Pro Gly Arg Gly Leu Glu Trp Ile

35 40 45

Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe

50 55 60

Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr

65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe Asn Val Trp Gly

100 105 110

Ala Gly Thr Thr Val Thr Val Ser Ala

115 120

<210> 8

<211> 109

<212> PRT

<213> Artificial sequence (artificial sequence)

<400> 8

Gln Ile Val Leu Ser Gln Ser Pro Ala Ile Leu Ser Ala Ser Pro Gly

1 5 10 15

Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Ile

20 25 30

His Trp Phe Gln Gln Lys Pro Gly Ser Ser Pro Lys Pro Trp Ile Tyr

35 40 45

Ala Thr Ser Asn Leu Ala Ser Gly Val Pro Val Arg Phe Ser Gly Ser

50 55 60

Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Val Glu Ala Glu

65 70 75 80

Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Thr Ser Asn Pro Pro Thr

85 90 95

Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val

100 105

<210> 9

<211> 120

<212> PRT

<213> Artificial sequence (artificial sequence)

<400> 9

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala

1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr

20 25 30

Asn Met His Trp Val Arg Gln Thr Pro Gly Gln Arg Leu Glu Trp Met

35 40 45

Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe

50 55 60

Lys Gly Arg Val Thr Ile Thr Ala Asp Thr Ser Ala Ser Thr Ala Tyr

65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe Asn Val Trp Gly

100 105 110

Gln Gly Thr Thr Val Thr Val Ser

115 120

<210> 10

<211> 109

<212> PRT

<213> Artificial sequence (artificial sequence)

<400> 10

Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly

1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Ile

20 25 30

His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr

35 40 45

Ala Thr Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser

50 55 60

Gly Ser Gly Thr Ser Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu

65 70 75 80

Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Trp Thr Ser Asn Pro Pro Thr

85 90 95

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val

100 105

<210> 11

<211> 120

<212> PRT

<213> Artificial sequence (artificial sequence)

<400> 11

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala

1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr

20 25 30

Asn Met His Trp Val Arg Gln Thr Pro Gly Gln Gly Leu Glu Trp Met

35 40 45

Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe

50 55 60

Lys Gly Arg Val Thr Met Thr Ala Asp Thr Ser Thr Ser Thr Val Tyr

65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe Asn Val Trp Gly

100 105 110

Gln Gly Thr Thr Val Thr Val Ser

115 120

<210> 12

<211> 120

<212> PRT

<213> Artificial sequence (artificial sequence)

<400> 12

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala

1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr

20 25 30

Asn Met His Trp Val Arg Gln Thr Pro Gly Gln Arg Leu Glu Trp Met

35 40 45

Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe

50 55 60

Lys Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr

65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe Asn Val Trp Gly

100 105 110

Gln Gly Thr Thr Val Thr Val Ser

115 120

<210> 13

<211> 119

<212> PRT

<213> Artificial sequence (artificial sequence)

<400> 13

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala

1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Tyr Asn

20 25 30

Met His Trp Val Arg Gln Thr Pro Gly Gln Gly Leu Glu Trp Met Gly

35 40 45

Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys

50 55 60

Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr Met

65 70 75 80

Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala

85 90 95

Arg Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe Asn Val Trp Gly Gln

100 105 110

Gly Thr Thr Val Thr Val Ser

115

<210> 14

<211> 120

<212> PRT

<213> Artificial sequence (artificial sequence)

<400> 14

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala

1 5 10 15

Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Phe Thr Ser Tyr

20 25 30

Asn Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met

35 40 45

Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe

50 55 60

Lys Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr

65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Thr Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe Asn Val Trp Gly

100 105 110

Gln Gly Thr Thr Val Thr Val Ser

115 120

<210> 15

<211> 120

<212> PRT

<213> Artificial sequence (artificial sequence)

<400> 15

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala

1 5 10 15

Ser Val Lys Val Ser Cys Lys Val Ser Gly Tyr Thr Phe Thr Ser Tyr

20 25 30

Asn Met His Trp Val Arg Gln Thr Pro Gly Lys Gly Leu Glu Trp Met

35 40 45

Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe

50 55 60

Lys Gly Arg Val Thr Met Thr Glu Asp Thr Ser Thr Asp Thr Ala Tyr

65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Thr Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe Asn Val Trp Gly

100 105 110

Gln Gly Thr Thr Val Thr Val Ser

115 120

<210> 16

<211> 109

<212> PRT

<213> Artificial sequence (artificial sequence)

<400> 16

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly

1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Ser Ser Val Ser Tyr Ile

20 25 30

His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr

35 40 45

Ala Thr Ser Asn Leu Ala Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser

50 55 60

Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu

65 70 75 80

Asp Phe Ala Val Tyr Tyr Cys Gln Gln Trp Thr Ser Asn Pro Pro Thr

85 90 95

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val

100 105

<210> 17

<211> 360

<212> DNA

<213> Artificial sequence (artificial sequence)

<400> 17

caggttcagc tggttcagtc tggcgccgaa gtgaagaaac ctggcgcctc tgtgaaggtg 60

tcctgcaagg ccagcggcta cacctttacc agctacaaca tgcactgggt ccgacagacc 120

cctggccaga gacttgaatg gatgggcgcc atctatcccg gcaacggcga cacctcctac 180

aaccagaaat tcaagggccg cgtgaccatc accagagaca catctgccag caccgcctac 240

atggaactga gcagcctgag aagcgaggac accgccgtgt actactgtgc cagaagcacc 300

tactacggcg gcgactggta cttcaatgtg tggggccagg gcaccaccgt gacagtttct 360

<210> 18

<211> 360

<212> DNA

<213> Artificial sequence (artificial sequence)

<400> 18

caggttcagc tggttcagtc tggcgccgaa gtgaagaaac ctggcgcctc tgtgaaggtg 60

tcctgcaagg ccagcggcta cacctttacc agctacaaca tgcactgggt ccgacagacc 120

cctggccaga gacttgaatg gatgggcgcc atctatcccg gcaacggcga cacctcctac 180

aaccagaaat tcaagggcag agtgaccatc accgccgaca catctgccag caccgcctac 240

atggaactga gcagcctgag aagcgaggac accgccgtgt actactgtgc cagaagcacc 300

tactacggcg gcgactggta cttcaatgtg tggggccagg gcaccaccgt gacagtttct 360

<210> 19

<211> 357

<212> DNA

<213> Artificial sequence (artificial sequence)

<400> 19

caggttcagc tggttcagtc tggcgccgaa gtgaagaaac ctggcgcctc tgtgaaggtg 60

tcctgcaagg ccagcggcta cacctttacc tacaacatgc actgggtccg acagacccct 120

ggacagggac ttgaatggat gggcgccatc tatcccggca acggcgacac cagctacaac 180

cagaaattca agggccgcgt gaccatgacc agagacacca gcacctccac cgtgtacatg 240

gaactgagca gcctgagaag cgaggacacc gccgtgtact actgtgccag aagcacctac 300

tacggcggcg actggtactt caatgtgtgg ggccagggca ccaccgtgac agtttct 357

<210> 20

<211> 360

<212> DNA

<213> Artificial sequence (artificial sequence)

<400> 20

caggttcagc tggttcagtc tggcgccgaa gtgaagaaac ctggcgcctc tgtgaaggtg 60

tcctgcaagg ccagcggcta cacctttacc agctacaaca tgcactgggt ccgacagaca 120

cctggacagg gactcgaatg gatgggcgcc atctatcccg gcaatggcga cacctcctac 180

aaccagaaat tcaagggcag agtgaccatg accgccgaca ccagcacaag caccgtgtac 240

atggaactga gcagcctgag aagcgaggac accgccgtgt actactgtgc cagaagcacc 300

tactacggcg gcgactggta cttcaatgtg tggggccagg gcaccaccgt gacagtttct 360

<210> 21

<211> 360

<212> DNA

<213> Artificial sequence (artificial sequence)

<400> 21

caggttcagc tggttcagtc tggcgccgaa gtgaagaaac ctggcgcctc tgtgaaggtg 60

tcctgcaagg tgtccggcta cacctttacc agctacaaca tgcactgggt ccgacaggcc 120

cctggcaaag gacttgaatg gatgggcgcc atctatcccg gcaacggcga cacctcctac 180

aaccagaaat tcaagggcag agtgaccatg accgaggaca ccagcaccga taccgcctac 240

atggaactga gcagcctgcg gagcgaagat accgccgtgt actactgtgc cacctccacc 300

tactatggcg gcgactggta cttcaacgtg tggggccagg gaaccaccgt gacagtttct 360

<210> 22

<211> 360

<212> DNA

<213> Artificial sequence (artificial sequence)

<400> 22

caggttcagc tggttcagtc tggcgccgaa gtgaagaaac ctggcgcctc tgtgaaggtg 60

tcctgcaagg tgtccggcta cacctttacc agctacaaca tgcactgggt ccgacagacc 120

cctggcaaag gccttgaatg gatgggcgcc atctatcccg gcaacggcga cacctcctac 180

aaccagaaat tcaagggcag agtgaccatg accgaggaca ccagcaccga taccgcctac 240

atggaactga gcagcctgcg gagcgaagat accgccgtgt actactgtgc cacctccacc 300

tactatggcg gcgactggta cttcaacgtg tggggccagg gaaccaccgt gacagtttct 360

<210> 23

<211> 327

<212> DNA

<213> Artificial sequence (artificial sequence)

<400> 23

gacatccagc tgacccagtc tccaagcttt ctgagcgcca gcgtgggcga cagagtgacc 60

attacatgta gagccagcag cagcgtgtcc tacatccact ggtatcagca gaagcccggc 120

aaggccccta agctgctgat ctacgccaca agcaatctgg ccagcggcgt gccaagcaga 180

ttttctggct ctggcagcgg caccagcttc accctgacca tatctagcct gcagcctgag 240

gacttcgcca cctactactg ccagcagtgg accagcaatc ctcctacctt tggcggaggc 300

accaaggtgg aaatcaagcg gacagtg 327

<210> 24

<211> 327

<212> DNA

<213> Artificial sequence (artificial sequence)

<400> 24

gagatcgtgc tgacacagtc tcccgccaca ctgtcactgt ctccaggcga aagagccaca 60

ctgagctgta gagccagcag cagcgtgtcc tacatccact ggtatcagca gaagcccgga 120

caggccccta gactgctgat ctacgccaca agcaatctgg ccagcggcat ccccgataga 180

ttttccggct ctggctccgg caccgacttc accctgacaa tcagcagact ggaacccgag 240

gacttcgccg tgtactactg ccagcagtgg accagcaatc ctcctacctt tggcggaggc 300

accaaggtgg aaatcaagcg gacagtg 327

Claims

1. An anti-CD 20 antibody, wherein the antibody has:

(1) the heavy chain variable region has a sequence shown in SEQ ID NO. 9; and

(2) and the sequence of the light chain variable region is shown as SEQ ID NO. 10.

2. The antibody of claim 1, wherein said antibody has a heavy chain having a heavy chain variable region and a heavy chain constant region; and a light chain having a light chain variable region and a light chain constant region.

3. A recombinant protein, said recombinant protein having:

(i) the antibody of claim 1; and

(ii) optionally a tag sequence to facilitate expression and/or purification.

4. An antibody preparation, comprising:

(a) the antibody of claim 1; and

(b) a vector, said vector comprising: buffer, sterile water, and optionally a surfactant.

5. A kit comprising the antibody of claim 1 and a container holding said antibody.

6. A CAR construct wherein the scFv of the antigen binding region of the CAR construct is a binding region that specifically binds to CD20 and wherein the scFv has a heavy chain variable region as set forth in SEQ ID No.9 and a light chain variable region as set forth in SEQ ID No. 10.

7. A recombinant immune cell expressing an exogenous CAR construct of claim 6.

8. An antibody drug conjugate, comprising:

(a) an antibody portion which is the antibody of claim 1; and

(b) a coupling moiety coupled to the antibody moiety, the coupling moiety selected from the group consisting of: a detectable label, a drug, a radionuclide, or a combination thereof.

9. The antibody drug conjugate of claim 8, wherein the drug comprises a toxin, a cytokine, and an enzyme.

10. Use of an active ingredient selected from the group consisting of: the antibody of claim 1, the recombinant protein of claim 3, the immune cell of claim 7, the antibody drug conjugate of claim 8, or a combination thereof, the active ingredient being for use

(a) Preparing a detection reagent or a kit;

11. A pharmaceutical composition, comprising:

(i) an active ingredient selected from the group consisting of: the antibody of claim 1, the recombinant protein of claim 3, the immune cell of claim 7, the antibody drug conjugate of claim 8, or a combination thereof; and

(ii) a pharmaceutically acceptable carrier, diluent or excipient.

12. A polynucleotide encoding a polypeptide selected from the group consisting of:

(1) the antibody of claim 1; or

(2) The recombinant protein of claim 3;

(3) the CAR construct of claim 6.

13. A vector comprising the polynucleotide of claim 12.

14. A genetically engineered host cell comprising the vector or genome of claim 13 having the polynucleotide of claim 12 integrated therein.

15. A method of preparing an engineered immune cell comprising the steps of:

(A) providing an immune cell to be modified; and

(B) introducing a first expression cassette into the immune cell to be engineered, wherein the first expression cassette expresses the CAR construct of claim 6, thereby obtaining an engineered immune cell.

16. A method for detecting CD20 protein in a sample in vitro, the method comprising the steps of:

(1) contacting the sample with the antibody of claim 1 in vitro;

17. A test board, said test board comprising: a substrate (support plate) and a test strip comprising the antibody of claim 1 or the antibody drug conjugate of claim 8.

18. A kit, comprising:

a first container, and a first nucleic acid sequence comprising a first expression cassette that expresses the CAR construct of claim 6 located within the first container.

19. A diagnostic kit, comprising:

a first container comprising the antibody of claim 1.

20. A diagnostic kit, comprising:

(1) a first container comprising the antibody of claim 1; and

(2) a second container comprising a secondary antibody against the antibody of claim 1.

21. A method of producing a recombinant polypeptide, said method comprising:

(a) culturing the host cell of claim 14 under conditions suitable for expression;

(b) isolating a recombinant polypeptide from the culture, said recombinant polypeptide being the antibody of claim 1 or the recombinant protein of claim 3.